Galapagos

Generaal De Wittelaan L 11A3

2800 Mechelen

BE

Galapagos

Foundation date

1999

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.

Upcoming events

Latest news

  • SeptiCyte® RAPID receives 510(k) clearance by US FDA

    1 day ago

  • QbD and Inovigate launch Health to Market, a contract commercialization organization in life sciences

    1 day ago

  • Dimitrios Mantzilas joins Precirix as Chief Technology Officer

    1 day ago